Distinct tumorigenic potential of abl and raf in B cell neoplasia: abl activates the IL-6 signaling pathway

被引:35
作者
Hilbert, DM
Migone, TS
Kopf, M
Leonard, WJ
Rudikoff, S
机构
[1] NHLBI,LAB MOL IMMUNOL,NIH,BETHESDA,MD 20892
[2] BASEL INST IMMUNOBIOL,CH-4005 BASEL,SWITZERLAND
关键词
D O I
10.1016/S1074-7613(00)80312-X
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The development of murine plasma cell tumors induced by raf/myc containing retroviruses is facilitated by T cells and completely dependent on IL-6. To determine whether kinases with differing specificities reflect alternative biochemical pathways in B cell tumorigenesis, we have employed an abl/myc containing retrovirus to assess neoplastic development. In contrast with raf/myc, abl/myc disease is T cell and IL-6 independent. An examination of the IL-6 signal transduction pathway reveals that this pathway, as defined by activation of Stat3, is inducible by IL-6 in raf/myc tumors but constitutively activated in abl/myc tumors. These findings provide a mechanism for the derivation of cytokine-independent plasma cell tumors and suggest that both IL-6-dependent and independent tumors may arise in vivo depending on the particular mutational events incurred during tumorigenesis.
引用
收藏
页码:81 / 89
页数:9
相关论文
共 77 条
[1]   MOLECULAR-CLONING OF APRF, A NOVEL IFN-STIMULATED GENE FACTOR-3 P91-RELATED TRANSCRIPTION FACTOR INVOLVED IN THE GP130-MEDIATED SIGNALING PATHWAY [J].
AKIRA, S ;
NISHIO, Y ;
INOUE, M ;
WANG, XJ ;
WEI, S ;
MATSUSAKA, T ;
YOSHIDA, K ;
SUDO, T ;
NARUTO, M ;
KISHIMOTO, T .
CELL, 1994, 77 (01) :63-71
[2]   INDUCTION OF PLASMA CELL TUMOURS IN BALB/C MICE WITH 2,6,10,14-TETRAMETHYLPENTADECANE (PRISTANE) [J].
ANDERSON, PN ;
POTTER, M .
NATURE, 1969, 222 (5197) :994-&
[3]  
BAST EJEG, 1982, CLIN EXP IMMUNOL, V47, P677
[4]   INTERLEUKINS AND IGA SYNTHESIS - HUMAN AND MURINE INTERLEUKIN-6 INDUCE HIGH-RATE IGA SECRETION IN IGA-COMMITTED B-CELLS [J].
BEAGLEY, KW ;
ELDRIDGE, JH ;
LEE, F ;
KIYONO, H ;
EVERSON, MP ;
KOOPMAN, WJ ;
HIRANO, T ;
KISHIMOTO, T ;
MCGHEE, JR .
JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 169 (06) :2133-2148
[5]   INTERLEUKIN-3 AND INTERLEUKIN-6 SYNERGISTICALLY PROMOTE THE PROLIFERATION AND DIFFERENTIATION OF MALIGNANT PLASMA-CELL PRECURSORS IN MULTIPLE-MYELOMA [J].
BERGUI, L ;
SCHENA, M ;
GAIDANO, G ;
RIVA, M ;
CALIGARISCAPPIO, F .
JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 170 (02) :613-618
[6]  
BILLADEAU D, 1992, BLOOD, V80, P1818
[7]   THE BONE-MARROW OF MULTIPLE-MYELOMA PATIENTS CONTAINS B-CELL POPULATIONS AT DIFFERENT STAGES OF DIFFERENTIATION THAT ARE CLONALLY RELATED TO THE MALIGNANT PLASMA-CELL [J].
BILLADEAU, D ;
AHMANN, G ;
GREIPP, P ;
VANNESS, B .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (03) :1023-1031
[8]   THE PLASMACYTOMA GROWTH INHIBITOR RESTRICTIN-P IS AN ANTAGONIST OF INTERLEUKIN-6 AND INTERLEUKIN-11 - IDENTIFICATION AS A STROMA-DERIVED ACTIVIN-A [J].
BROSH, N ;
STERNBERG, D ;
HONIGWACHSSHAANANI, J ;
LEE, BC ;
SHAV-TAL, Y ;
TZEHOVAL, E ;
SHULMAN, LM ;
TOLEDO, J ;
HACHAM, Y ;
CARMI, P ;
JIANG, W ;
SASSE, J ;
HORN, F ;
BURSTEIN, Y ;
ZIPORI, D .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (49) :29594-29600
[9]  
CASSEL A, 1990, EXP HEMATOL, V18, P1171
[10]   JAK-STAT SIGNALING INDUCED BY THE V-ABL ONCOGENE [J].
DANIAL, NN ;
PERNIS, A ;
ROTHMAN, PB .
SCIENCE, 1995, 269 (5232) :1875-1877